AZT studies reinforce benefits of combination.
D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015496:CD4-Positive T-Lymphocytes; D016049:Didanosine / Q000008:administration & dosage / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine; D018655:Lymphocyte Count; D016047:Zalcitabine / Q000008:administration & dosage / Q000627:therapeutic use*; D015215:Zidovudine / Q000008:administration & dosage / Q000627:therapeutic use*
D000998:Antiviral Agents; D019259:Lamivudine; D015215:Zidovudine; D016047:Zalcitabine; D016049:Didanosine